Hokkaido University Collection of Scholarly and Academic Papers >
Hokkaido University Hospital >
Peer-reviewed Journal Articles, etc >
Dipeptidyl peptidase-4 inhibitor might exacerbate Graves' disease : A multicenter observational case-control study
Title: | Dipeptidyl peptidase-4 inhibitor might exacerbate Graves' disease : A multicenter observational case-control study |
Authors: | Sekizaki, Tomonori Browse this author | Kameda, Hiraku Browse this author →KAKEN DB | Nomoto, Hiroshi Browse this author | Cho, Kyu Yong Browse this author | Nakamura, Akinobu Browse this author | Takahashi, Kiyohiko Browse this author | Miyoshi, Arina Browse this author | Wada, Norio Browse this author | Takeuchi, Jun Browse this author | Nagai, So Browse this author | Miyoshi, Hideaki Browse this author | Atsumi, Tatsuya Browse this author |
Keywords: | Dipeptidyl peptidase-4 | Graves' disease | Case-control study |
Issue Date: | 15-Jul-2021 |
Publisher: | John Wiley & Sons |
Journal Title: | Journal of diabetes investigation |
Volume: | 12 |
Issue: | 11 |
Start Page: | 1978 |
End Page: | 1982 |
Publisher DOI: | 10.1111/jdi.13578 |
Abstract: | Dipeptidyl peptidase-4 (DPP-4), namely CD26, is expressed on the surface of immune cells, suggesting that inhibition of DPP-4 might affect the immune system. The current multicenter observational case-control study was carried out to investigate the effects of DPP-4 inhibitor (DPP-4i) administration on Graves' disease (GD) activity. This study comprised patients with GD and type 2 diabetes, who were administered an oral hypoglycemic agent including DPP-4i. Exacerbation of GD was defined as an increase of antithyroid drug dose by 6 months after oral hypoglycemic agent administration. A total of 80 patients were enrolled and divided into an exacerbation group or a non-exacerbation group. The frequency of DPP-4i administration was significantly higher in the exacerbation group (88%) than that in the non-exacerbation group (31%). In multivariate logistic regression analysis, there was a significant association between DPP-4i administration and GD exacerbation (odds ratio 7.39). The current study suggests that DPP-4i administration is associated with GD exacerbation. |
Type: | article |
URI: | http://hdl.handle.net/2115/82226 |
Appears in Collections: | 北海道大学病院 (Hokkaido University Hospital) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
|